Immix Biopharma Gains 25% As Its Pediatric Cancer Treatment Gets FDA’s RPD Designation

Walmart Temporarily Closes About 60 US Stores In Dec. For COVID Cleaning

Walmart temporarily shut down nearly 60 U.S. stores in COVID-19 hotspots in December for deep cleaning and sanitizing amid rising Covid-19 cases of the Omicron variant, Reuters reported.

The retail giant, which has more than 4,700 U.S. locations in total, closed stores in various locations, including Texas and New Jersey, for two days for cleaning.

Meanwhile, Walmart is yet to confirm whether there were Covid cases among staff at the closed locations.

At the start of the coronavirus pandemic two years ago, Walmart reportedly had adopted a policy of closing stores for fewer than two days to get ahead of potential outbreaks.

The Centers for Disease Control and Prevention or CDC recommends that if a sick person or someone who tested positive for COVID-19 has been in a facility, it closes off areas used by the person who is sick and do not use those areas until after cleaning and disinfecting.

Rising COVID-19 cases, mainly among staff, are forcing several retailers and restaurant chains to temporarily close their facilities in various places across the country.

The United States witnessed unprecedented levels of surge in coronavirus infection cases of the Omicron variant over the past weekend. Average daily infections reportedly were 405,470, rising by more than 200 percent in a period of two weeks.

Pre-market Movers: IMMX, VALN, LQDA, OSAT, EKSO…

The following are some of the stocks making big moves in Tuesday’s pre-market trading (as of 07.20 A.M. ET).

In the Green

Immix Biopharma, Inc. (IMMX) is up over 18% at $6.85
Liquidia Corporation (LQDA) is up over 13% at $5.82
Orbsat Corp. (OSAT) is up over 13% at $4.00
Ekso Bionics Holdings, Inc. (EKSO) is up over 13% at $3.12
Usio, Inc. (USIO) is up over 11% at $4.92
Clene Inc. (CLNN) is up over 9% at $4.85
uCloudlink Group Inc. (UCL) is up over 8% at $4.13
Borr Drilling Limited (BORR) is up over 8% at $2.35
UpHealth, Inc. (UPH) is up over 7% at $2.80

In the Red

Valneva SE (VALN) is down over 15% at $42.93
Select Energy Services, Inc. (WTTR) is down over 10% at $6.00
Creative Medical Technology Holdings, Inc. (CELZ) is down over 10% at $2.88
Eco Wave Power Global AB (publ) (WAVE) is down over 9% at $5.45
Jowell Global Ltd. (JWEL) is down over 8% at $8.05
Armstrong Flooring, Inc. (AFI) is down over 7% at $2.56
Centogene N.V. (CNTG) is down over 6% at $5.06

Ian King Business Podcast: COVID staff shortages, foreign takeovers shake-up and an alcohol-free brewery

All the latest as a rise in Omicron coronavirus cases hits the return to work with staff forced to isolate. Ian speaks to business minister Lord Callanan as new rules which make it harder for foreign takeovers of UK firms, considered key to national security, come into effect. Plus, more on Nirvana Brewery – the UK’s only dedicated alcohol-free brewery.

Yamaha launches 2022 FZS-Fi

Yamaha has updated the FZS-Fi for 2022 with prices for the bike starting at ₹ 1.16 lakh. Aside from minor updates, the motorcycle gets a new Dlx variant priced at ₹ 1.19 lakh (ex-showroom).

The 2022 FZS-Fi gets Bluetooth connectivity as standard and costs ₹ 1,000 more than the Bluetooth-equipped 2021 model. The only other change is the new LED tail-lamp; the bike is available in the colour options of matte blue and matte red.

While the FZS-Fi Dlx also gets the new LED tail-lamp, it comes with LED turn signals, which Yamaha says will be installed by dealers as an accessory at no extra cost. Also exclusive to the Dlx variant are the new graphics schemes, unique colour options and coloured wheels. Two of the Dlx’s three colour options also get a contrasting shade for the seat.

There are no mechanical changes and the bike continues to be powered by a single-cylinder, air-cooled 149cc engine producing 12.4hp and 13.3Nm.

Soligenix: Dusquetide Effective At Reducing Tumor Size In Nonclinical Xenograft Models

Soligenix, Inc. (SNGX) said recent studies, recapitulating results from previously published studies, have confirmed the efficacy of dusquetide as a stand-alone and combination anti-tumor therapy, with radiation, chemotherapy and targeted therapy. Based on the biological proof of principle shown both nonclinically and clinically with dusquetide, the company continues to explore product opportunities, both in the reduction of oral mucositis in head and neck cancer and as a potential anti-cancer treatment.

Christopher Schaber, CEO of Soligenix, said: “With the supportive data from the phase 2 and 3 oral mucositis trials, and the nonclinical anti-tumor efficacy demonstrated, we continue to pursue potential partnership for this novel molecule.”

Shares of Soligenix were up 26% in pre-market trade on Tuesday.

General Electric Up 3%

Shares of General Electric Co. (GE) are up 3 percent on Tuesday’s trading despite there being no company specific news to influence the stock.

General Electric is an American multinational conglomerate headquartered in Boston. The company mainly operates in the sectors of aviation, power, renewable energy and digital industry.

Currently at $99.76, the stock has traded between $83.36 and $116.17 during the past 52 weeks.

Herald morning quiz: January 5

Test your brains with the Herald’s morning quiz. Be sure to check back on for the afternoon quiz.

To challenge yourself with more quizzes, CLICK HERE.

Immix Biopharma Gains 25% As Its Pediatric Cancer Treatment Gets FDA’s RPD Designation

Shares of Immix Biopharma, Inc. (IMMX) are gaining nearly 25% on Tuesday morning. The other day, the U.S. Food and Drug Administration granted Rare Pediatric Disease (RPD) designation for Immix Biopharma’s IMX-110 for the treatment of a life-threatening form of pediatric cancer in children, rhabdomyosarcoma.

IMMX is currently trading at $7.18, up $1.40 or 24.31%, on the Nasdaq.

IMX-110, an investigational product, is currently being evaluated in a Phase 1b/2a clinical trial. It is a tissue-specific therapeutic that simultaneously attacks all 3 components of the tumor micro-environment, severing the critical lifelines between the tumor and its metabolic and structural support.

The FDA grants Rare Pediatric Disease designation for serious and life-threatening diseases that primarily affect children aged 18 years or younger and impact fewer than 200,000 people in the U.S.

Rhabdomyosarcoma is a high-grade, malignant neoplasm, the most common soft tissue sarcoma in pediatric and adolescent populations and which rarely occurs in adults. The prevalence of RMS in the United States is approximately 20,000 children of all ages. The five-year survival rate ranges from 20% to 30% for children in the high-risk group where cancer spreads widely in the body.